Reported 1 day ago
Guggenheim has reiterated a 'Buy' rating for AbbVie Inc. (NYSE:ABBV) with a price target of $227. In its recent Q2 2025 results, AbbVie reported a diluted EPS of $0.52, a 32.5% decrease, while adjusted diluted EPS rose by 12.1% to $2.97. Net revenues for the quarter reached $15.423 billion, reflecting a 6.6% increase. The report highlights AbbVie's strengths as a pharmaceutical leader in treating severe health conditions, despite some analysts suggesting AI stocks might offer better investment potential.
Source: YAHOO